[Urinary hydroxyproline in advanced breast carcinoma and response to treatment with medroxyprogesterone acetate (MAP) in high doses].
The Authors have studied total urinary hydroxyproline (TUH), together with other hematochemical analyses, in 104 patients suffering from advanced breast cancer with or without bone metastases. TUH escretion is higher in patients with osseous lesions and, if simultaneous pathologic values of TUH and serum alcaline phosphatase occur, the presence of bone metastases is statistically even more probable. Moreover TUH seems to vary in accordance with the clinical response of the disease at osseous level in 46 patients treated with Medroxyprogesterone acetate (MPA) at high doses, showing itself as a possible marker of not negligible clinical value.
D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000652:urine; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000652:urine; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000652:urine*; D008525:Medroxyprogesterone / Q000494:pharmacology / Q000627:therapeutic use*; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000652:urine
D008525:Medroxyprogesterone; D006909:Hydroxyproline
Idrossiprolina urinaria nel carcinoma mammario avanzato e risposta al trattamento con medrossiprogesterone acetato (MAP) ad alte dosi.